EZH2 targeting in medulloblastoma reduces tumor growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway

Medulloblastoma is a malignant pediatric tumor for which new therapies are urgently needed. We demonstrate that treatment with EPZ-6438 (Tazemetostat), an enhancer of zeste homologue 2 (EZH2) inhibitor approved for clinical trials, blocks MB cell growth in vitro and in vivo, and prolongs survival in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hanwen, Zhu, Dan, Zhang, Zhaobin, Kaluz, Stefan, Yu, Bing, Devi, Narra S., Olson, Jeffrey J., Van Meir, Erwin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780546/
https://www.ncbi.nlm.nih.gov/pubmed/31582835
http://dx.doi.org/10.1038/s41388-019-1036-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780546/
https://www.ncbi.nlm.nih.gov/pubmed/31582835
http://dx.doi.org/10.1038/s41388-019-1036-7

Ejemplares similares